Molecular diagnostics

This is a good article. Click here for more information.
Source: Wikipedia, the free encyclopedia.

Specialist using "QIAsymphony", an automation platform for molecular diagnostic tests

Molecular diagnostics is a collection of techniques used to analyze

livestock disease, estimate risk, and decide what quarantine measures must be taken.[3]

By analysing the specifics of the patient and their disease, molecular diagnostics offers the prospect of personalised medicine.[4] These tests are useful in a range of

immune function), coagulation, and pharmacogenomics—the genetic prediction of which drugs will work best.[5]: v-vii  They overlap with clinical chemistry
(medical tests on bodily fluids).

History

Molecular diagnostics uses techniques such as mass spectrometry and gene chips to capture the expression patterns of genes and proteins

The field of molecular biology grew in the late twentieth century, as did its clinical application. In 1980,

restriction enzymes that cut DNA where they recognised specific short sequences, creating different lengths of DNA strand depending on which allele (genetic variation) the fetus possessed.[6] In the 1980s, the phrase was used in the names of companies such as Molecular Diagnostics Incorporated[7] and Bethseda Research Laboratories Molecular Diagnostics.[8][9]

During the 1990s, the identification of newly discovered genes and new techniques for DNA sequencing led to the appearance of a distinct field of molecular and genomic laboratory medicine; in 1995, the Association for Molecular Pathology (AMP) was formed to give it structure. In 1999, the AMP co-founded The Journal of Medical Diagnostics.

genetic hybridization tests to identify the specific single nucleotide polymorphism causing an individual's disease.[11]

As the commercial application of molecular diagnostics has become more important, so has

the U.S. Supreme Court partially agreed, ruling that a naturally occurring gene sequence could not be patented.[13][14]

Techniques

The Affymetrix 5.0, a microarray chip

Development from research tools

The industrialisation of molecular biology assay tools has made it practical to use them in clinics.

clinical laboratory requires high standards of reliability; diagnostics may require accreditation or fall under medical device regulations.[15] As of 2011, some US clinical laboratories nevertheless used assays sold for "research use only".[16]

Laboratory processes need to adhere to regulations, such as the

Good Laboratory Practice, and Food and Drug Administration specifications in the United States. Laboratory Information Management Systems help by tracking these processes.[17] Regulation applies to both staff and supplies. As of 2012, twelve US states require molecular pathologists to be licensed; several boards such as the American Board of Medical Genetics and the American Board of Pathology certify technologists, supervisors, and laboratory directors.[18]

Automation and sample barcoding maximise throughput and reduce the possibility of error or contamination during manual handling and results reporting. Single devices to do the assay from beginning to end are now available.[15]

Assays

Main articles:
Biological assay

Molecular diagnostics uses in vitro

RNAse enzymes. Samples can be snap-frozen in liquid nitrogen or incubated in preservation agents.[2]
: ch 39 

Because molecular diagnostics methods can detect sensitive markers, these tests are less intrusive than a traditional

antibodies to bind and hence can detect many different proteins in parallel.[24] Molecular diagnostic tests vary widely in sensitivity, turn around time, cost, coverage and regulatory approval. They also vary in the level of validation applied in the laboratories using them. Hence, robust local validation in accordance with the regulatory requirements and use of appropriate controls is required especially where the result may be used to inform a patient treatment decision.[25]

Benefits

A microarray chip contains complementary DNA (cDNA) to many sequences of interest. The cDNA fluoresces when it hybridises with a matching DNA fragment in the sample.

Prenatal

See also: Category:Tests during pregnancy

Conventional prenatal tests for

genomic hybridisation test a sample of DNA instead, and because of cell-free DNA in plasma, could be less invasive, but as of 2013 it is still an adjunct to the conventional tests.[26]

Treatment

Main article: Pharmacogenomics

Some of a patient's

Silver-Russell syndrome.[1][29]

Infectious disease

See also: Pathogenomics

Molecular diagnostics are used to identify infectious diseases such as

chromatographic profile.[36] Molecular diagnostics are also used to understand the specific strain of the pathogen—for example by detecting which drug resistance genes it possesses—and hence which therapies to avoid.[36] In addition, assays based on metagenomic next generation sequencing can be implemented to identify pathogenic organisms without bias.[37]

Disease risk management

See also: Screening (medicine) and Genetic testing

A patient's genome may include an inherited or random mutation which affects the probability of developing a disease in the future.

Cardiovascular risk is indicated by biological markers and screening can measure the risk that a child will be born with a genetic disease such as Cystic fibrosis.[39] Genetic testing is ethically complex: patients may not want the stress of knowing their risk.[40] In countries without universal healthcare, a known risk may raise insurance premiums.[41]

Cancer

See also: Tumor metabolome

micro RNA molecules, which cancerous cells express more of than healthy ones.[44]

Cancer is a disease with excessive molecular causes and constant evolution. There's also heterogeneity of disease even in an individual. Molecular studies of cancer have proved the significance of driver mutations in the growth and metastasis of tumors.[45] Many technologies for detection of sequence variations have been developed for cancer research. These technologies generally can be grouped into three approaches: polymerase chain reaction (PCR), hybridization, and next-generation sequencing (NGS).[22] Currently, a lot of PCR and hybridization assays have been approved by FDA as in vitro diagnostics.[46] NGS assays, however, are still at an early stage in clinical diagnostics.[47]

To do the molecular diagnostic test for cancer, one of the significant issue is the DNA sequence variation detection. Tumor biopsy samples used for diagnostics always contain as little as 5% of the target variant as compared to wildtype sequence. Also, for noninvasive applications from peripheral blood or urine, the DNA test must be specific enough to detect mutations at variant allele frequencies of less than 0.1%.[22]

Currently, by optimizing the traditional PCR, there's a new invention, amplification-refractory mutation system (ARMS) is a method for detecting DNA sequence variants in cancer. The principle behind ARMS is that the enzymatic extension activity of DNA polymerases is highly sensitive to mismatches near the 3' end of primer.[22] Many different companies have developed diagnostics tests based on ARMS PCR primers. For instance, Qiagen therascreen,[48] Roche cobas[49] and Biomerieux THxID[50] have developed FDA approved PCR tests for detecting lung, colon cancer and metastatic melanoma mutations in the KRAS, EGFR and BRAF genes. Their IVD kits were basically validated on genomic DNA extracted from FFPE tissue.

There are also microarrays that utilize hybridization mechanism to diagnose cancer. More than a million of different probes can be synthesized on an array with Affymetrix's Genechip technology with a detection limit of one to ten copies of mRNA per well.[22] Optimized microarrays are typically considered to produce repeatable relative quantitation of different targets.[51] Currently, FDA have already approved a number of diagnostics assays utilizing microarrays: Agendia's MammaPrint assays can inform the breast cancer recurrence risk by profiling the expression of 70 genes related to breast cancer;[52] Autogenomics INFNITI CYP2C19 assay can profile genetic polymorphisms, whose impacts on therapeutic response to antidepressants are great;[53] and Affymetrix's CytoScan Dx can evaluate intellectual disabilities and congenital disorders by analyzing chromosomal mutation.[54]

In the future, the diagnostic tools for cancer will likely to focus on the Next Generation Sequencing (NGS). By utilizing DNA and RNA sequencing to do cancer diagnostics, technology in the field of molecular diagnostics tools will develop better. Although NGS throughput and price have dramatically been reduced over the past 10 years by roughly 100-fold, we remain at least 6 orders of magnitude away from performing deep sequencing at a whole genome level.[22] Currently, Ion Torrent developed some NGS panels based on translational AmpliSeq, for example, the Oncomine Comprehensive Assay.[55] They are focusing on utilizing deep sequencing of cancer-related genes to detect rare sequence variants.

Molecular diagnostics tool can be used for cancer risk assessment. For example, the BRCA1/2 test by Myriad Genetics assesses women for lifetime risk of breast cancer.[22] Also, some cancers are not always employed with clear symptoms. It is useful to analyze people when they do not show obvious symptoms and thus can detect cancer at early stages. For example, the ColoGuard test may be used to screen people over 55 years old for colorectal cancer.[56] Cancer is a longtime-scale disease with various progression steps, molecular diagnostics tools can be used for prognosis of cancer progression. For example, the OncoType Dx test by Genomic Health can estimate risk of breast cancer. Their technology can inform patients to seek chemotherapy when necessary by examining the RNA expression levels in breast cancer biopsy tissue.[57]

With rising government support in DNA molecular diagnostics, it is expected that an increasing number of clinical DNA detection assays for cancers will become available soon. Currently, research in cancer diagnostics are developing fast with goals for lower cost, less time consumption and simpler methods for doctors and patients.

See also

References

  1. ^
    PMID 11901792
    .
  2. ^
    ISBN 978-1-4557-5942-2
    .
  3. ^ "About ITP". ITP. Retrieved 23 April 2021.
  4. S2CID 205106671
    .
  5. ISBN 978-0-12-369428-7
    .
  6. PMID 6927915
    .
  7. PMID 6233131
    .
  8. PMID 3928684
    .
  9. PMID 6961188
    .
  10. PMC 1906886
    .
  11. PMID 24052746
    .
  12. ^ Sharples A (23 March 2011). "Gene Patents in Europe Relatively Stable Despite Uncertainty in the U.S." Genetic Engineering and Biotechnology News. Retrieved 13 June 2013.
  13. ^ Bravin J, Kendall B (13 June 2013). "Justices Strike Down Gene Patents". The Wall Street Journal. Retrieved 15 June 2013.
  14. ^ Barnes R, Brady D (13 June 2013). "Supreme Court rules human genes may not be patented". The Washington Post. Retrieved 15 June 2013.
  15. ^
    Genetic Engineering & Biotechnology News. Retrieved 4 September 2013. {{cite journal}}: Cite journal requires |journal= (help
    )
  16. Genetic Engineering & Biotechnology News. Retrieved 4 September 2013. {{cite journal}}: Cite journal requires |journal= (help
    )
  17. ^ Tomiello K (21 February 2007). "Regulatory compliance drives LIMS". Design World. Retrieved 7 November 2012.
  18. PMID 22925695
    .
  19. ISBN 978-1-904933-19-9
    .
  20. PMID 7549423
    .
  21. doi:10.1309/LM6ER9WJR1IHQAUY
    .
  22. ^
    PMID 27089811
    .
  23. PMID 24956168
    .
  24. PMID 12067604
    .
  25. PMID 29018576
    .
  26. ^ "Advances in Prenatal Molecular Diagnostics Conference (Introduction)". HealthTech. 2013. Archived from the original on 18 September 2013. Retrieved 28 September 2013.
  27. ^ a b c d "Molecular Diagnostics - National Cancer Institute". Cancer.gov. 28 January 2005. Archived from the original on 26 September 2006. Retrieved 26 September 2013.
  28. S2CID 27616494
    .
  29. S2CID 3427029
    .
  30. S2CID 26518693
    .
  31. S2CID 207219269
    .
  32. PMID 16706743
    .
  33. S2CID 894775
    .
  34. PMID 33595397
    .
  35. S2CID 24649273
    .
  36. ^
    PMID 9365385
    .
  37. PMID 30918369
    .
  38. PMID 19929944
    .
  39. S2CID 27351636
    .
  40. PMID 15467071
    .
  41. ^ Harmon, Amy (24 February 2008) Insurance Fears Lead Many to Shun DNA Tests. New York Times
  42. S2CID 26732113
    .
  43. S2CID 23540973
    .
  44. S2CID 45371217
    .
  45. PMID 22722830
    .
  46. PMID 21871973
    .
  47. ^ FDA-approved next-generation sequencing system could expand clinical genomic testing: experts predict MiSeqDx platform will make genetic testing more affordable for smaller labs. AM. J. Med. Genet. A 164, X-XI.
  48. PMID 22952784
    .
  49. PMID 22713664
    .
  50. PMID 25037456
    .
  51. PMID 21098318
    .
  52. PMID 18483364
    .
  53. PMID 21385571
    .
  54. PMID 25880438
    .
  55. PMID 25925381
    .
  56. PMID 25006736
    .
  57. PMID 26119102
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Molecular_diagnostics&oldid=1212943858"